These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22257652)

  • 21. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
    Nahta R; O'Regan RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
    Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
    Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating the HER2 pathway in early and advanced breast cancer.
    Pegram MD
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual HER2-targeted approaches in HER2-positive breast cancer.
    Ahn ER; Vogel CL
    Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
    Khasraw M; Bell R
    Expert Rev Anticancer Ther; 2012 Aug; 12(8):1005-13. PubMed ID: 23030220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib: current status and future directions in breast cancer.
    Moy B; Goss PE
    Oncologist; 2006; 11(10):1047-57. PubMed ID: 17110623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual blockade of HER2 - twice as good or twice as toxic?
    Fralick M; Hilton JF; Bouganim N; Clemons M; Amir E
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):593-603. PubMed ID: 22748560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting alternative pathways in HER2-positive breast cancer.
    Rastogi P
    Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
    [No Abstract]   [Full Text] [Related]  

  • 35. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer.
    Banerjee S
    Steroids; 2011 Jul; 76(8):807-11. PubMed ID: 21439993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 37. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hints of future progress for HER-2 breast cancer.
    Twombly R
    J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
    Patil A; Sherbet GV
    Cancer Lett; 2015 Mar; 358(2):93-99. PubMed ID: 25529010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
    Huemer F; Gampenrieder SP; Schlattau A; Greil R
    Clin Breast Cancer; 2014 Feb; 14(1):e17-20. PubMed ID: 24246725
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.